The treatment of acute venous thromboembolism (VTE) is being completely modified with
the development of direct oral anticoagulants (DOACs). Rivaroxaban, apixaban and …

Background Current guidelines recommend the use of direct oral anticoagulants (DOACs)
for patients with venous thromboembolism (VTE). However little is known about the use of …

Background Real-world data on the impact of advances in risk-adjusted management on the
outcome of patients with pulmonary embolism (PE) are limited. Methods To investigate …

In patients with venous thromboembolism (VTE), the influence on outcome of using direct
oral anticoagulants (DOACs) at non-recommended doses or regimens (once vs twice daily) …

Abstract Introduction Direct oral anticoagulants (DOACs) are increasingly prescribed for life-
long anticoagulation in chronic thromboembolic pulmonary hypertension (CTEPH) patients …

The emergence of direct oral anticoagulants (DOACs) represents a major advancement and
paradigm shift in the treatment of venous thromboembolism. Currently, dabigatran …

Letter to the Editor The optimal management of acute pulmonary embolism remains a
compelling challenge. In recent years, with the improvement of prognostic stratification, it …

Pulmonary embolism (PE), which can develop as a consequence of deep vein thrombosis
(DVT), is a serious and potentially fatal venous thromboembolic event. Patients with PE are …

What is known and Objective Direct oral anticoagulants (DOACs) are frequently used for the
treatment of pulmonary embolism (PE), but both clinical and laboratory data comparing their …

Pulmonary embolism (PE) is a frequent, serious and multifactorial disease, the incidence of
which increases with advanced age. In the absence of pathognomonic clinical signs or …